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Background: The imbalance between proteases and antiproteases has been proposed to participate to the
pathogenesis of chronic obstructive pulmonary disease (COPD) and emphysema. Gene level variation in different
metalloproteinases, metalloproteinase inhibitors, and cytokines affecting them may contribute to this imbalance
and destruction of the lung parenchyma. We investigated whether polymorphisms in selected protease-
antiprotease balance pathway genes predispose to different emphysema subtypes (centrilobular, paraseptal,
panlobular, and bullae) and airflow limitation among Finnish construction workers.
Methods: Eleven single nucleotide polymorphisms (SNPs) from seven genes (GC: rs7041 and rs4588; MMP1:
rs1799750; MMP9: rs3918242; MMP12: rs652438; TIMP2: rs2277698; TNF: rs1799724 and rs1800629; TGFB1: rs1800469,
rs1800470, and rs2241718) were analyzed from 951 clinically and radiologically characterized construction workers.
The genotype and haplotype data was compared to different emphysematous signs confirmed with high
resolution computed tomography (HRCT), forced vital capacity (FVC), forced expiratory volume in one second
(FEV1), and maximal expiratory flow at 50% of FVC (MEF50) by using linear and logistic regression analyses, adjusted
for potential confounders.
Results: The TIMP2 rs2277698 SNP was associated with overall (p = 0.022) and paraseptal (p = 0.010) emphysema, as
well as with FEV1/FVC ratio (p = 0.035) and MEF50 (p = 0.008). The TGFB1 rs2241718 and MMP9 rs3918242 SNPs were
associated with centrilobular emphysema (p = 0.022 and p = 0.008), and the TNF rs1800629 SNP with paraseptal
emphysema (p = 0.017). In stratified analysis, individuals with at least one TIMP2 rs2277698 or TNF rs1800629 variant
allele were found to be at around two-fold risk for pathological paraseptal changes (OR 1.94, 95% CI 1.14-3.30; OR
2.10, 95% CI 1.24-3.56). On the contrary, the risk for pathological centrilobular changes was halved for individuals
with at least one MMP9 rs3918242 (OR 0.51, 95% CI 0.30-0.86) or TGFB1 rs2241718 (OR 0.53, 95% CI 0.30-0.90) variant
allele, or TGFB1 rs1800469-rs1800470 AT-haplotype (OR 0.55, 95% CI 0.33-0.93). MEF50, in turn, was significantly
reduced among individuals with at least one TIMP2 rs2277698 variant allele (p = 0.011).
Conclusion: Our findings strengthen the hypothesis of the importance of protease-antiprotease balance in
pathogenesis of emphysema and shed light on the aetiology of different emphysema subtypes by associating
MMP9 and TGFB1 to centrilobular emphysema, and TIMP2 and TNF to paraseptal emphysema and/or airflow
obstruction.
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The imbalance between proteases and antiproteases is
widely accepted as a mechanism behind the lung tissue
destruction leading to pulmonary emphysema [1,2]. This
theory has been building up since the discovery of severe
deficiency of a serine protease inhibitor Alpha-1-antitrypsin
(encoded by SERPINA1 gene), which has been shown to
predispose to early panlobular emphysema [3]. Subse-
quently, the gene of another member of the serpin-family,
SERPINE2, has been associated to chronic obstructive
pulmonary disease (COPD) and emphysema in several
populations [4-7]. In agreement with this, our recent find-
ings suggested that SERPINE2 gene polymorphisms may
be involved particularly in the development of panlobular
emphysema [8].
In addition to the serine proteases, there are a number
of proteolytic enzymes capable of degrading elastin and
other matrix macromolecules, such as the matrix metal-
oproteinases (MMPs). MMPs play an essential role in
tissue repair and remodeling, and there is increasing evi-
dence that some of them may be important in airway
inflammation and the development of COPD and em-
physema [2]. It has been shown that transgenic mice
over-expressing MMP1 or MMP9 develop pulmonary
changes comparable to human emphysema [9,10], and
that mice lacking the MMP12 gene are protected from
emphysema despite a long term exposure to cigarette
smoke [11]. Furthermore, several polymorphisms in
MMP1, MMP9, and MMP12 genes have been associated
to emphysema and related phenotypes [12-15].
Tissue inhibitors of metalloproteinases (TIMPs), in
turn, may contribute to the disturbance of protease-
antiprotease balance by binding MMPs and inhibiting
their actions. In fact, variation in the TIMP2 gene has
been associated to the development of COPD in two
different populations [16,17]. In addition, differences in
the expression of TGFB1 and TNF cytokines have been
shown to influence the pathogenesis of COPD in animal
models, possibly via interactions with MMP9 and MMP12
[18-20]. Genetic association studies have connected sev-
eral polymorphisms and/or haplotypes of TGFB1 and
TNF genes to the development of COPD [21-24], and
recent meta-analyses have confirmed some of the asso-
ciations [25,26].
GC (Group specific component; also known as Vitamin
D-binding protein, VDBP) is a multifunctional protein,
suggested to have a role in chronic inflammatory response
in the lungs [27]. Certain polymorphisms in the GC gene
have previously been associated to COPD [28,29].
We investigated whether polymorphisms in the
GC gene (rs7041 and rs4588) and six genes of the
protease-antiprotease balance (MMP1: rs1799750; MMP9:
rs3918242; MMP12: rs652438; TIMP2: rs2277698; TNF:
rs1799724 and rs1800629; TGFB1: rs1800469, rs1800470,and rs2241718) predispose to emphysematous changes
and airflow limitation among Finnish Caucasian construc-
tion workers. These polymorphisms were selected based
on previous association studies suggesting them as poten-
tial modifiers of the examined pulmonary disorders.
Signs of emphysema subtypes (centrilobular, paraseptal,
panlobular, and bullae) were determined from all the study
subjects by using the high-resolution computed tomog-
raphy (HRCT) –technique. Lung function was measured
by using flow volume spirometry.
Methods
Study population
This study combines data from two previous screening
studies. The first study group (ASBE, n = 602) was
recruited in 1996–1997 and consisted of asbestos ex-
posed subjects who lived in Helsinki area, had asbestosis
or asbestos-related pleural plaques, and had a positive
smoking history [30,31]. The second study group (ASSE,
n = 633) was recruited in 2003–2004 and consisted of as-
bestos exposed persons from three geographic areas
(Helsinki, Tampere, Turku), who had previously been di-
agnosed with an asbestos related occupational disease,
or had visited the clinics of occupational medicine in
Helsinki, Turku or Tampere for a clinical follow-up [32].
Altogether 178 of the subjects recruited in 2003–2004
had already participated in the first study. They were
therefore excluded from the second patient group in the
present study before combining the data. In the com-
bined study population, blood samples were available for
1021 subjects, 1013 of whom the genotype data were
successfully achieved. However, 25 additional subjects
were excluded because of missing smoking information
and 37 because of insufficient asbestos exposure data.
Thus, the final study group consisted of 951 subjects
(935 males, 16 females).
An approval for the study was obtained from the local
ethics committees (Ethical Committee of the Finnish
Institute of Occupational Health and Ethics Committee
for Research in Occupational Health and Safety, Hospital
District of Helsinki and Uusimaa) according to the legis-
lation at the time of the original study. All subjects gave
an informed consent to participate in the study.
Radiological examinations
The lungs of the construction workers were imaged
prone in full inspiration with four different scanners: in
1996–1997 the Picker PO 2000 (Picker International,
Cleveland, USA) device was used, whereas in 2003–2004
Siemens Somatom Balance (Siemens Medical, Erlangen,
Germany) was used in Helsinki, Siemens Somatom Plus
4 (Siemens Medical) was used in Tampere, and GE
Light-speed 16 Advantage (GE Healthcare, Milwaukee,
WI, USA) was used in Turku.
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analyzed blindly by two (2003–2004) or three (1996–
1997) radiologists. Emphysema was defined as sharply
delineated low-density area(s) according to the criteria
and reference images given by Webb et al. [33]. The
radiologic signs of centrilobular, paraseptal, panlobular,
and bullae-type emphysema were scored in both lungs
by using a scale from 0 to 5 (the emphysema subtype
score): 0 (no changes), 1 (faint or subnormal abnormal-
ities, in a single slice or few slices), 2 (slight abnormal-
ities in some slices), 3 (clear abnormalities in several
slices), 4 (score between 3 and 5), and 5 (abnormalities
widely distributed in the whole lung, in all or most
slices). These emphysema subtype scores were added up
to form the emphysema sum score, its maximum being
20 per lung [31]. Mean scores of both lungs were used
in the analysis. The intra- and inter-reader consistencies
of readings have previously been reported [30].
Lung function examinations
Flow-volume spirometry was performed with a rolling-
seal spirometer (Mijnhard BV, Bunnik, Holland) con-
nected to microcomputer (Medikro MR-3; Medikro,
Kuopio, Finland), using Finnish reference values [34]
and the standards of the European Respiratory Society
(ERS) [35]. The following parameters were measured:
forced vital capacity (FVC), forced expiratory volume in
1 second (FEV1), the FEV1/FVC ratio (FEV1/FVC × 100),
and the maximal expiratory flow where 50% of FVC re-
mains exhaled (MEF50).
The FVC, FEV1, and MEF50 were handled as percent
of Finnish reference values [34] based on the distribution
of values in the reference population. The FEV1 and
FVC values were considered decreased if they were
<80% of predicted, FEV1/FVC ratio if it was <88% of
predicted, and MEF50 if it was <62% of predicted [34].
Genotyping analyses
DNA was extracted mechanically (Thermo King Fisher;
Thermo Fisher Scientific, Erembodegem, Belgium) from
whole blood using Biosprint 15 DNA Blood Kit (Qiagen
GmbH, Hilden, Germany) and stored at −20°C until use.
Two TNF SNPs (rs1799724 and rs1800629), two TGFB1
SNPs (rs1800469 and rs2241718), two GC SNPs (rs7041
and rs4588), oneMMP12 SNP (rs652438), and one TIMP2
SNP (rs2277698) were genotyped by using the Open
Array-system (BioTrove Inc., Woburn, MA, USA), a next-
generation quantitative PCR platform based on TaqMan
chemistry. The assay ID:s for TaqMan® SNP Genotyping
Assays spotted on the array were C__11918223_10,
C___7514879_10, C___8708473_10, C___7818377_1_,
C___3133594_30, C___8278879_10, C____785907_10, and
C__15885241_10, respectively. Plate format of 16 SNPs
and 144 samples per array was used. The allele callinganalysis was performed by using OpenArray™ SNP Geno-
typing Analysis software (BioTrove Inc.).
The third analysed TGFB1 SNP (rs1800470) was geno-
typed by using an allelic discrimination assay on the ABI
7500 Real-Time PCR system (Applied Biosystems, Foster
City, CA, USA) with TaqMan® probes [36]. The primers
and probes used in the assay were as follows: forward
primer: 5′-GCG CTC TCG GCA GTG C-3′; reverse
primer: 5′-CCA GGC GTC AGC ACC AGT A-3′; VIC-
probe: 5′-AGC AGC GGC AGC A-3′; and FAM-probe:
5′-CAG CAG CAG CAG C-3′. The primer and probe
concentrations in the PCR reaction were 1200 nM and
200 nM, respectively, and the cycling conditions were
50°C for 2 minutes, 95°C for 10 minutes, 40 cycles of 95°C
for 15 seconds, and 62°C for 1 minute. Sequence Detection
Software 1.4 (Applied Biosystems) was used for the allele
calling analysis.
The MMP1 SNP (rs1799750) was analysed with
a pyrosequencing-method based on an assay from
PyroMark Assay Database (Qiagen). The PCR-primers
were: forward primer 5′-biotin-CCC TTA TGG ATT
CCT GTT TTC-3′; reverse primer: 5′-CCC ATT CTT
CTT ACC CTC TTG-3′.
The primer concentrations in PCR reactions were 500
nM, and the cycling conditions were: 95°C for 5 minutes,
35 cycles of 95°C for 30 seconds, 54°C for 30 seconds,
and 72°C for 30 seconds followed by a final extension of
72°C for 5 minutes. The pyrosequencing run was
performed with PSQ™96MA (Qiagen) by using Pyromark
Gold Q96 Reagents (Qiagen) according to manufac-
turer’s recommendations. Briefly, 40 μl of the PCR prod-
uct was mixed with 37 μl of Binding buffer and 3 μl of
Streptavidin Sepharose High Performance beads (GE
Healthcare, Uppsala, Sweden). PCR products bound to
the beads were collected and denatured to single-
stranded by treatment with 70% Ethanol (Aa), Denatur-
ation Buffer, Washing Buffer, and mQ water in
Pyrosequencing Washing Station. The sequencing pri-
mer 5′-GTA GTT AAA TAA TTA GAA AG-3′ was
attatched to the template by incubating for 2 minutes
in 80°C in annealing buffer. The Pyrosequencing
run was conducted in the dispensation order of
CAGCTACTAGCA. The pyrograms were generated
and analyzed with PSQ 96 SNP Software 1.1.
The MMP9 SNP (rs3918242) was genotyped by using
a PCR-RFLP-based method essentially according to Joos
et al. [37]. Briefly, the concentrations of the forward
(5′-TTC GTG ACG CAA AGC AGA-3′) and reverse (5′-
AGC AGC CTC CCT CAC TCC T-3′) primers were 670
nM, and the cycling conditions were 95°C for 4 minutes,
34 cycles of 95°C for 30 seconds, 58°C for 30 sec-
onds, and 72°C for 45 seconds followed by a final
extension of 72°C for 5 minutes. After digestion with
SphI in 37°C for 3 hours the PCR product was
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and visualized under UV-light.
For the quality control, two independent readers
interpreted the results and a random selection of 10% of
all samples was re-tested. No discrepancies were discov-
ered in the replicate tests for rs7041, rs4588, rs652438,
rs1800470, rs1799750, and rs3918242. Minor error rates
were detected for OpenArray assays rs1799724 (1%),
rs1800629 (2%), rs2241718 (2%), rs2277698 (2%), and
rs1800469 (3%).
To verify the reliability of OpenArray platform, a ran-
dom selection of 15% of samples was re-analyzed for
rs1800629 and rs1799724 with 100% concordant results
with the earlier estimates.
The re-analyses were conducted with an RFLP-based
method [38] (rs1800629) and a pyrosequencing-based
method (rs1799724). The primers and probes for the
pyrosequencing protocol designed by using PyroMark
Assay Design 1.0 -tool (Qiagen) were as follows: forward
primer: 5′-GGTAGG AGA ATG TCC AGG GCTATG-3′,
biotinylated reverse primer: 5′-biotin-ACT CCC TGG GGC
CCT CTA-3′ and sequencing primer: 5′-TCG AGT ATG
GGG ACC-3′. The primer concentrations in PCR reactions
were 200 nM, and the cycling conditions were: 95°C for
5 minutes, 39 cycles of 95°C for 15 seconds, 56°C for
30 seconds, and 72°C for 15 seconds followed by a final
extension of 72°C for 5 minutes. The pyrosequencing was
performed with PSQ™96MA (Qiagen) by using Pyromark
Gold Q96 Reagents (Qiagen) as described above for the
analysis of the MMP1 rs1799750 SNP.Statistical analysis
Our study (n = 951) has 80% power to detect odds ratios
(ORs) from 1.46 to 2.30 depending on the minor allele fre-
quency (4-42%). The calculations, based on a two-sided
alpha of 0.05, were performed by using standard methods.
The χ2 analysis with a cut-off p-value of 0.05 was used
to test for a deviation from the Hardy-Weinberg equilib-
rium (HWE).Table 1 Distribution of radiologic signs in relation to emphys
No changes Any changes
n (%) n (%)
Emphysema‡ 599 (63.0) 352 (37.0)
Centrilobular 723 (76.0) 228 (24.0)
Paraseptal 781 (82.1) 170 (17.9)
Panlobular 783 (82.3) 168 (17.7)
Bullae 826 (86.9) 125 (13.1)
*The changes were considered as subnormal if the radiologic score was < 1 (< 2 in
†The changes were considered as pathological if the radiologic score ≥ 1 (≥ 2 in em
‡The sum score of all emphysematous changes.The linkage disequilibrium (LD) structure was examined
by using HaploView program, version 4.2 [39]. When mod-
erate or strong linkage was detected (r2 > 0.5), haplotypes
consisting of the SNPs in question were statistically
reconstructed from population genotype data with the
Markov chain method for haplotype assignments by using
the PHASE program (version 2.1) [40]. The associations
of the haplotypes to pulmonary parameters were then
examined as with the single SNPs.
The associations between genotypes/haplotypes, emphy-
sema, and lung function parameters (FEV1, FVC, FEV1/
FVC and MEF50) were evaluated by using general linear
model, whereas logistic regression analysis was used to
evaluate the potential confounders and to further study the
risk for emphysematous changes and their severity with
certain genotype. For further analysis, the cases were di-
vided according to the existence of radiologic changes
(Table 1). The radiologic signs of emphysema were then
considered either subnormal if the emphysema subtype
score was <1 (<2 in emphysema sum score), or pathological
if the emphysema subtype score was ≥1 (≥2 in emphysema
sum score).
Covariates used in the analysis were: sex, age, pack years
of smoking (PYs) and years of asbestos exposure for em-
physema, and PYs and years of asbestos exposure for FEV1,
FVC, FEV1/FVC ratio, and MEF50.
All of the data analyses were performed by using the
SPSS version 18.0 (SPSS Inc., Chicago, IL).
Results
The demographics, pulmonary function data, and HRCT
characteristics of the construction workers are summa-
rized in Table 2. The genotype frequencies of the studied
SNPs among subjects with different type of emphysema-
tous changes are shown in an additional table [see
Additional file 1: Table S1]. All the genotype distributions
of the studied gene polymorphisms were in HWE in the
whole study population (p > 0.09).
The TIMP2 rs2277698 was associated with emphysema
sum score (p= 0.022) and paraseptal emphysema (p= 0.010).ema subtypes
Radiologic signs
Subnormal changes* Pathological changes†
n (%) n (%)
231 (24.3) 121 (12.7)
105 (11.0) 123 (13.0)
94 (9.9) 76 (8.0)
109 (11.5) 59 (6.2)
90 (9.4) 35 (3.7)
emphysema sum score).
physema sum score).
Table 2 Selected characteristics of the construction
workers
Mean (SD) or N (%)
Age, years 63.2 (7.3)
Male sex 935 (98.3%)
Smoking history
Never smoker 135 (14.2%)
Ex-smoker 595 (62.6%)
Current smoker 221 (23.2%)
Pack years 20.4 (16.7)
Years of asbestos exposure (n = 943) 23.9 (10.7)
Emphysema score (n = 352*) 2.00 (2.38)
Centrilobular (n = 228) 1.23 (1.01)
Paraseptal (n = 170) 1.00 (0.91)
Panlobular (n = 168) 0.93 (0.87)
Bullae (n = 126) 0.70 (0.77)
Lung function
FEV1 (n = 925) 83.4 (18.6)
FVC (n = 921) 89.1 (15.9)
FEV1/FVC ratio (n = 921) 93.5 (12.8)
MEF50 (n = 923) 65.9 (29.5)
FEV1 = Forced expiratory volume in 1 second, % predicted; FVC = forced vital
capacity, % predicted; FEV1/FVC ratio = FEV1/FVC x 100; MEF50 =maximal
expiratory flow at 50% of forced vital capacity, % predicted; SD = standard
deviation, n = 951 except as otherwise noted.
*Subjects with emphysema sum score >0.
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sociated with centrilobular emphysema (p= 0.022 and p=
0.008, respectively), and the TNF rs1800629 SNP was associ-
ated with paraseptal emphysema (p= 0.017) (Table 3).
The above mentioned association between TIMP2
rs2277698 SNP and emphysema sum score did not come
up in stratified analysis. Instead, the carriage of at leastTable 3 Association between genetic polymorphisms,
emphysema and pulmonary function
Phenotype Gene Polymorphism β* p-value
Emphysema
All TIMP2 rs2277698 (G/A) 0.071 0.022
Centrilobular TGFB1 rs2241718 (G/A) −0.071 0.022
MMP9 rs3918242 (C/T) −0.082 0.008
Paraseptal TNF rs1800629 (G/A) 0.075 0.017
TIMP2 rs2277698 (G/A) 0.081 0.010
FEV1/FVC ratio TIMP2 rs2277698 (G/A) −0.066 0.035
MEF50 TIMP2 rs2277698 (G/A) −0.084 0.008
FEV1/FVC ratio = FEV1/FVC x 100; MEF50 =maximal expiratory flow at 50% of
forced vital capacity, % predicted; Covariates used in the analysis: sex, age,
PYs, and years of asbestos exposure for emphysema scores; pack-years and
years of asbestos exposure for MEF50.
*Standardized coefficient β.one TIMP2 rs2277698 variant A-allele was found to pose
a twofold risk for pathological paraseptal emphysema
(OR 1.94, 95% CI 1.14-3.30) (Table 4). In addition, the
carriage of at least one TNF rs1800629 variant A-allele
was found to pose a twofold risk for overall (OR 2.03,
95% CI 1.38-2.98), subnormal (OR 2.12, 95% CI 1.30-
3.48), and pathological (OR 2.10, 95% CI 1.24-3.56)
paraseptal changes. In contrast, the carriage of at least
one TGFB1 rs2241712 variant A-allele was found to
halve the risk for centrilobular emphysema (OR 0.53,
95% CI 0.30-0.90), as was also the carriage of at least
one MMP9 rs3918242 variant T-allele (OR, 0.51 95% CI
0.30-0.86) (Table 4).
The TIMP2 rs2277698 was also found to be associ-
ated with the FEV1/FVC ratio (p = 0.035) and MEF50
(p = 0.008). In further analysis, subjects with at least
one TIMP2 rs2277698 variant A-allele were found to
have significantly lower MEF50 than subjects with
homozygous TIMP2 rs2277698 wild type genotype
(61.0 ± 27.0 vs. 67.0 ± 29.9, p = 0.011). Similarly, the
FEV1/FVC ratio tended to be lower among subjects
homozygous to the TIMP2 rs2277698 variant A-allele
compared to the wild type genotype (89.1 ±9.3 vs.
93.8 ± 12.7, p = 0.136).
When gene-gene interactions were examined, a com-
bination of homozygous variant allele genotypes of
TGFB1 rs2241718 and MMP9 rs3918242 loci was
found to reduce the risk of pathological centrilobular
changes into fifth compared to the wild type genotypes
(OR 0.22, CI 95% 0.08-0.61) (Table 5).
In the linkage analyses, linkage disequilibrium was
observed between the GC rs4588 and rs7041 SNPs (D’ =
1.00, r2 = 0.501). The TGFB1 rs1800469 and rs1800470
SNPs were also linked to each other (D’ = 0.970, r2 = 0.738),
but not with the third studied TGFB1 SNP (rs2241712)
(D’ <0.02 and r2 = 0.0). The TNF rs1799724 minor allele
frequency was too small 0.2%) for r2 to detect LD, despite
of the maximum D’ (D’ = 1.00, r2 = 0.008).
Haplotype analysis identified three haplotypes for GC
rs4588 and rs7041 SNPs; the most common haplotype
(65.2%) was GC (wild type-wild type), followed by GA
(13.7%), and TA (21.1%) haplotypes. No associations
were seen between the GC haplotypes and the studied
parameters.
For TGFB1 rs1800469 and rs1800470 SNPs four hap-
lotypes were identified: GT (wild type-wild type,
60.5%), GC (24.9%), AT (10.3%), and AC (4.3%). The
TGFB1 haplotype (rs1800469-rs1800470) was found to
be associated with centrilobular emphysema (p = 0.018)
(data not shown). Moreover, in the stratified analysis
the AT haplotype was found to almost halve the risk
for centrilobular emphysema (OR 0.55, 95% CI 0.33-
0.93) compared to the most common haplotype (GT)
(Table 6).
Table 4 Distribution of TIMP2, TGFB1, MMP9, and TNF genotypes according to the existence and severity of
emphysema changes
Emphysema
phenotype
Genotype No radiologic
changes*
Radiologic
changes
OR (95% CI)† Subnormal‡
changes
OR (95% CI)† Pathological§
changes
OR (95% CI)†
n (%) n (%) n (%) n (%)
All TIMP2
rs2277698
G/G 462 (77.9) 270 (77.8) 1.0 180 (79.6) 1.0 90 (74.4) 1.0
G/A or A/A 131 (22.1) 77 (22.2) 1.02 (0.72-1.44) 46 (20.4) 0.92 (0.62-1.38) 31 (25.6) 1.35 (0.83-2.22)
Centrilobular TGFB1
rs2241718
G/G 518 (72.8) 173 (77.6) 1.0 74 (71.2) 1.0 99 (83.2) 1.0
G/A or A/A 194 (27.2) 50 (22.4) 0.76 (0.52-1.11) 30 (28.8) 1.08 (0.68-1.73) 20 (16.8) 0.53 (0.30-0.90)
MMP9
rs3918242
C/C 519 (72.5) 171 (75.7) 1.0 74 (70.5) 1.0 97 (80.2) 1.0
C/T or T/T 197 (27.5) 55 (24.3) 0.77 (0.53-1.12) 31 (29.5) 1.08 (0.68-1.72) 24 (19.8) 0.51 (0.30-0.86)
Paraseptal TIMP2
rs2277698
G/G 609 (78.9) 123 (73.2) 1.0 72 (78.3) 1.0 51 (67.1) 1.0
G/A or A/A 163 (21.1) 45 (26.8) 1.41 (0.94-2.13) 20 (21.7) 1.04 (0.59-1.81) 25 (32.9) 1.94 (1.14-3.30)
TNF
rs1800629
G/G 605 (78.3) 111 (66.1) 1.0 61 (66.3) 1.0 50 (65.8) 1.0
G/A or A/A 168 (21.7) 57 (33.9) 2.03 (1.38-2.98) 31 (33.7) 2.12 (1.30-3.48) 26 (34.2) 2.10 (1.24-3.56)
Data are presented as n (%) except as noted.
*Reference category.
†Adjusted for age, sex, pack-years and years of asbestos exposure.
‡The changes were considered as subnormal if the emphysema subtype score was < 1 (< 2 in emphysema sum score).
§The changes were considered as pathological if the emphysema subtype score was ≥ 1 (≥ 2 in emphysema sum score).
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We found a significant association between MMP9
rs3918242 variant T-allele and a lowered proneness to
centrilobular emphysema. This contrasts the previous
findings suggesting the T-allele as a risk factor for COPD
and emphysema that is dominant in the upper lungTable 5 Distribution of MMP9/TGFB1 combined genotypes ac
changes
Genotype combination
(MMP9 rs3918242-
TGFB1 rs2241718)
No radiologic
changes *
Radiologic
changes
OR (95% C
n (%) n (%)
Wild type-wild type# 375 (52.8) 130 (58.3) 1.0
Heterozygote/
homozygote+
281 (39.6) 81 (36.3) 0.83 (0.60-1.1
Heterozygotes or
homozygotes±
54 (7.6) 12 (5.4) 0.63 (0.36-1.0
*Reference category.
†Adjusted for age, sex, pack-years and years of asbestos exposure.
‡The changes were considered as subnormal if the emphysema subtype score was
§The changes were considered as pathological if the emphysema subtype score wa
#MMP9 CC/TGFB1 GG.
+MMP9 CT/TGFB1 GG or MMP9 CC/TGFB1 GA.
±MMP9 CT/TGFB1 GA or MMP9 TT or TGFB1 AA.[12,13]. However, similarly to our study, a recent Korean
study with a reasonable study size found the T-allele
protective against COPD [41].
In addition to MMP9, several animal and genetic stud-
ies have connected MMP1 and MMP12 to COPD and
emphysema [9,11,42]. We did not, however, find anycording to the existence and severity of centrilobular
I)† Subnormal‡
changes
OR (95% CI)† Pathological§
changes
OR (95% CI)†
n (%) n (%)*
52 (50.0) 1.0 78 (65.5) 1.0
5) 43 (41.3) 1.07 (0.69-1.68) 38 (31.9) 0.66 (0.43-1.02)
9) 9 (8.7) 1.29 (0.68-2.46) 3 (2.5) 0.22 (0.08-0.61)
< 1 (< 2 in emphysema sum score).
s ≥ 1 (≥ 2 in emphysema sum score).
Table 6 Distribution of TGFB1 haplotypes according to the existence and severity of centrilobular changes
Haplotype*
No radiologic
changes
Radiologic
changes
OR (95% CI)‡ Subnormal§
changes
OR (95% CI)‡ Pathological#
changes
OR (95% CI)‡
n (%)† n (%)† n (%)† n (%)†
GT 834 (57.7) 283 (62.1) 1.0 125 (59.5) 1.0 158 (64.2) 1.0
GC 398 (27.5) 119 (26.1) 0.88 (0.68-1.14) 52 (24.8) 0.91 (0.64-1.30) 67 (27.2) 0.90 (0.65-1.26)
AT 187 (12.9) 50 (11.0) 0.79 (0.55-1.13) 30 (14.3) 1.10 (0.71-1.72) 20 (8.1) 0.55 (0.33-0.93)
AC 27 (1.9) 4 (0.9) 0.44 (0.15-1.32) 3 (1.4) 0.72 (0.21-2.44) 1 (0.4) 0.22 (0.03-1.70)
*Composed of rs1800469 and rs1800470 SNPs.
†Data are presented as number of chromosomes (%).
‡Adjusted for age, sex, pack-years and years of asbestos exposure.
§The changes were considered as subnormal if the emphysema subtype score was <1 (< 2 in emphysema sum score).
#The changes were considered as pathological if the emphysema subtype score was ≥1 (≥ 2 in emphysema sum score).
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emphysema or lung functions decline.
The previous studies on TGFB1 polymorphisms, COPD,
emphysema, and related traits have provided contradictory
results; some studies have found the variant alleles to pre-
dispose to emphysema and severe airflow limitation
[23,24] while others have found them to protect against
COPD [21,25].
In the current study, the TGFB1 rs2241718 SNP and a
haplotype consisting of the rs1800469 and rs1800470
SNPs were found to be associated with centrilobular
emphysema. Stratified analysis showed that the variant
A-allele in rs2241718 locus and a haplotype consisting
of rs1800469 variant A-allele and rs1800470 wild-type
T-allele were protective against pathological centrilobular
changes. Together with the MMP9 rs3918242 variant
T-allele the TGFB1 rs2241718 variant A-allele reduced
the risk of pathological centrilobular emphysema into
fifth compared to the wild-type genotype.
Both TGFB1 and MMP9 can be secreted from alveolar
macrophages, which are activated by cigarette smoke
and found in increased number in airways and lung par-
enchyma of COPD patients [1]. Centrilobular emphysema,
on the other hand, is the most common type of pulmon-
ary emphysema and closely associated to cigarette smoke
[43,44]. Hence, the effects of TGFB1 and MMP9 polymor-
phisms in the development of centrilobular disease could
be mediated through macrophages via interaction with
cigarette smoke. The studied SNPs in TGFB1 and MMP9
are also in strong linkage (r2 > 0.8 in 1000 Genomes Pro-
ject population) with several other polymorphisms, and it
is therefore possible that the causal variant resides in a
completely different gene.
Although TIMP2 polymorphisms have previously been
connected to COPD [16,17], their association to differ-
ent emphysema subtypes has remained unexplored.
In our study, the TIMP2 rs2277698 SNP was associ-
ated with overall and paraceptal emphysema, FEV1/
FVC ratio, and MEF50. Stratified analysis revealed atwofold risk for pathological paraseptal changes for
individuals with at least one variant A-allele. In
addition, FEV1/FVC ratio tended to be lower among
individuals homozygous with variant A-allele, and
MEF50 was significantly reduced among individuals
with at least one variant A-allele. Decreased FEV1/
FVC ratio and MEF50 suggests obstruction in per-
ipheral airways typical for COPD and smoking re-
lated emphysema [45].
The rs2277698 SNP is a synonymous base-substitution
with unknown functional consequences. Although it has
previously been speculated to associate with down regu-
lation of TIMP2 activity leading to matrix degradation
and COPD [16], this has remained unconfirmed.
The F-SNP program, connected to main databases
(http://compbio.cs.queensu.ca/F-SNP/) [46], predicts that
rs2277698 SNP is highly likely involved in splicing regula-
tion. The rs2277698 is also in strong linkage (r2 > 0.9 in
1000 Genomes Project population) with other SNPs, some
of which (rs9889410 and rs11654470) reside in an area
predicted to alter the transcriptional regulation [46].
We also found an association between the TNF
rs1800629 SNP and paraseptal emphysema. Further ana-
lysis revealed a twofold risk for pathological paraseptal
changes for individuals with at least one variant A-allele.
This finding is in agreement with a recent meta-analysis
with over 5500 COPD patients and controls [25], while
another meta-analysis suggests that the risk of developing
COPD is statistically significant only among Asian
subjects [26].
Since the rs1800629 variant A-allele has been shown
to enhance the expression of TNF [47], and since the
over-expression of TNF has been shown to induce em-
physematous changes in mouse models [20,48], our find-
ings support the role of TNF polymorphisms in the
development of pulmonary emphysema, and their in-
volvement in the pathogenesis of the paraseptal disease.
Certain genotypes and haplotypes of the multifunctional
GC-protein, suggested to have a role in macrophage
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lungs, has been associated to COPD in several studies
[28,29]. We did not, however, find any associations be-
tween these particular genotypes or haplotypes and em-
physema subtypes or lung function.
One of the main strengths of our study is that lung
function and CT-defined emphysema subtypes were
recorded separately and classified according to their
severity; it is highly likely that the disease pathogen-
esis vary between different subgroups. Another advan-
tage is that our patient material was considerably
large and a lot of ex- and current smokers were in-
cluded. This is useful in demonstrating the genetic
predisposition to emphysema, which probably would
not have manifested to such degree without smoking.
Our study also has some potential limitations. First,
since the patients were enrolled in three cities during
two separate primary studies, four different CT-
scanners were used and seven radiologists participated
in the image reading. However, since the Finnish
population is very homogenous and the three cities,
where the patients were enrolled, are all located in
the southern Finland very close to each other, we do
not believe that the geographic origin has caused any
significant bias in the data analysis. Moreover, any in-
consistency in image reading or in the technical
image quality causes inaccuracy and thus random
noise to the results leading in loss of power rather
than in a systematic error. This increases the error
variance in computations and the detected associa-
tions are therefore likely to be underestimated.
Second, our study subjects have been selected based
on their asbestos exposure, which itself appeared not to
be a significant predictor for emphysematous changes
in the logistic regression model (data not shown). How-
ever, it is highly likely that the study subjects have also
been occupationally exposed to other particles, such as
concrete, silica, and wood dusts, which can contribute
to the development of emphysema. Unfortunately the
exposure data of other dusts was not available from our
study subjects. However, like tobacco smoke, exposure
to these substances is likely to promote the detection of
genetic predisposition to emphysema.
Third, the multiple comparisons performed increase
the possibility of detecting false-positive associations.
However, most of the methods correcting for multiple
testing are very conservative, and it is not clear, e.g.,
what is the correct number of comparisons one
should adjust for [49]. In addition, based on previous
findings, we had an a priori hypothesis for each poly-
morphism chosen, which reduces the need for such
correction. Yet, these results should be considered
with caution until replicated in another study
population.Conclusions
To conclude, our findings support the hypothesis of the
importance of protease-antiprotease balance in patho-
genesis of emphysema and shed light on the aetiology of
different emphysema subtypes. In particular, polymor-
phisms in MMP9 and TGFB1 are proposed to protect
against centrilobular emphysema, and polymorphisms in
TIMP2 and TNF seem to increase the risk for paraseptal
emphysema and/or airflow obstruction.
Additional file
Additional file 1: Table S1. Genotype frequencies of the studied SNPs.
Abbreviations
AAT: Alpha-1-antitrypsin; ASBE: Patient group recruited in 1996–1997;
ASSE: Patient group recruited in 2003–2004; COPD: Chronic obstructive
pulmonary disease; CT: Computed tomography; GC: Group specific
component; FEV1: Forced expiratory volume in 1 second, % predicted;
FVC: Forced vital capacity, % predicted; HRCT: High resolution computed
tomography; HWE: Hardy-Weinberg equilibrium; LD: Linkage disequilibrium;
MEF50: Maximal expiratory flow where 50% of FVC remains exhaled;
MMP: Matrix metalloproteinase; MMP1: Matrix metalloproteinase 1 (interstitial
collagenase); MMP9: Matrix metalloproteinase 9 (gelatinase); MMP12: Matrix
metalloproteinase 12 (macrophage elastase); PY: Pack-years; SERPINA1: Serpin
peptidase inhibitor, clade A, member 1; SERPINE2: Serpin peptidase inhibitor,
clade E, member 2; SNP: Single nucleotide polymorphism;
TGFB1: Transforming growth factor, beta 1; TIMP2: Tissue inhibitor of
metalloproteinases 2; TNF: Tumor necrosis factor; VDBP: Vitamin D binding
protein (see also GC).
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MKK carried the main responsibility of the genotyping, data analyses, and
preparation of the manuscript; ET participated in the genotyping analyses
and manuscript preparation; TV participated in the data collection,
radiological examinations, data analysis, and manuscript preparation; PO
participated in the data collection and manuscript preparation; PP
participated in data collection, planning and analysis of lung function
examinations, and manuscript preparation; AH was responsible for the study
design and supervision of the genotyping, data analysis, and the manuscript
preparation. All authors have read and approved the final version of the
manuscript.
Acknowledgements
The authors thank Sirpa Hyttinen for the assistance with genotyping and
sample management and Pauliina Toivio for the help with data handling.
This study was financially supported by the Finnish Work Environment Fund
(Grants 109374 and 111332), Orion-Farmos Research Foundation, and ECNIS
(Environmental Cancer Risk, Nutrition and Individual Susceptibility), a network
of excellence operating within the European Union 6th Framework Program,
Priority 5: “Food Quality and Safety” (Contract No 513943).
Author details
1Finnish Institute of Occupational Health, Topeliuksenkatu 41 a A, FI-00250,
Helsinki, Finland. 2Department of Clinical Physiology, Helsinki University
Hospital, Helsinki, Finland.
Received: 14 November 2012 Accepted: 29 May 2013
Published: 4 June 2013
References
1. Barnes PJ, Shapiro SD, Pauwels RA: Chronic obstructive pulmonary
disease: molecular and cellular mechanisms. Eur Respir J 2003, 22:672–688.
Kukkonen et al. BMC Pulmonary Medicine 2013, 13:36 Page 9 of 10
http://www.biomedcentral.com/1471-2466/13/362. Abboud RT, Vimalanathan S: Pathogenesis of COPD. Part I. The role of
protease-antiprotease imbalance in emphysema. Int J Tuberc Lung Dis
2008, 12:361–367.
3. Tomashefski JF Jr, Crystal RG, Wiedemann HP, Mascha E, Stoller JK: The
bronchopulmonary pathology of alpha-1 antitrypsin (AAT) deficiency:
findings of the Death Review Committee of the national registry for
individuals with Severe Deficiency of Alpha-1 Antitrypsin. Hum Pathol
2004, 35:1452–1461.
4. DeMeo D, Mariani T, Lange C, Lake S, Litonjua A, Celedon J, Reilly J,
Chapman HA, Sparrow D, Spira A, et al: The SERPINE2 gene is associated
with chronic obstructive pulmonary disease. Proc Am Thorac Soc
2006, 3:502.
5. Zhu G, Warren L, Aponte J, Gulsvik A, Bakke P, Anderson WH, Lomas DA,
Silverman EK, Pillai SG: The SERPINE2 gene is associated with chronic
obstructive pulmonary disease in two large populations. Am J Respir Crit
Care Med 2007, 176:167–173.
6. Fujimoto K, Ikeda S, Arai T, Tanaka N, Kumasaka T, Ishii T, Kida K, Muramatsu
M, Sawabe M: Polymorphism of SERPINE2 gene is associated with
pulmonary emphysema in consecutive autopsy cases. BMC Med Genet
2010, 11:159.
7. Kim WJ, Hoffman E, Reilly J, Hersh C, Demeo D, Washko G, Silverman EK:
Association of COPD candidate genes with computed tomography
emphysema and airway phenotypes in severe COPD. Eur Respir J
2011, 37:39–43.
8. Kukkonen MK, Tiili E, Hämäläinen S, Vehmas T, Oksa P, Piirilä P, Hirvonen A:
SERPINE2 haplotype as a risk factor for panlobular type of emphysema.
BMC Med Genet 2011, 12:157.
9. D’Armiento J, Dalal SS, Okada Y, Berg RA, Chada K: Collagenase expression
in the lungs of transgenic mice causes pulmonary emphysema. Cell
1992, 71:955–961.
10. Foronjy R, Nkyimbeng T, Wallace A, Thankachen J, Okada Y, Lemaitre V,
D'Armiento J: Transgenic expression of matrix metalloproteinase-9
causes adult-onset emphysema in mice associated with the loss of
alveolar elastin. Am J Physiol Lung Cell Mol Physiol 2008,
294:L1149–1157.
11. Hautamäki RD, Kobayashi DK, Senior RM, Shapiro SD: Requirement for
macrophage elastase for cigarette smoke-induced emphysema in mice.
Science 1997, 277:2002–2004.
12. Ito I, Nagai S, Handa T, Muro S, Hirai T, Tsukino M, Mishima M: Matrix
metalloproteinase-9 promoter polymorphism associated with upper lung
dominant emphysema. Am J Respir Crit Care Med 2005, 172:1378–1382.
13. Tesfaigzi Y, Myers OB, Stidley CA, Schwalm K, Picchi M, Crowell RE, Gilliland
FD, Belinsky SA: Genotypes in matrix metalloproteinase 9 are a risk factor
for COPD. Int J Chron Obstruct Pulmon Dis 2006, 1:267–278.
14. Haq I, Chappell S, Johnson SR, Lotya J, Daly L, Morgan K, Guetta-Baranes T,
Roca J, Rabinovich R, Millar AB, et al: Association of MMP-12
polymorphisms with severe and very severe COPD: a case control study
of MMPs-1, 9 and 12 in a European population. BMC Med Genet
2010, 11:7.
15. Hunninghake GM, Cho MH, Tesfaigzi Y, Soto-Quiros ME, Avila L, Lasky-Su J,
Stidley C, Melen E, Soderhall C, Hallberg J, et al: MMP12, lung function, and
COPD in high-risk populations. N Engl J Med 2009, 361:2599–2608.
16. Hirano K, Sakamoto T, Uchida Y, Morishima Y, Masuyama K, Ishii Y, Nomura
A, Ohtsuka M, Sekizawa K: Tissue inhibitor of metalloproteinases-2 gene
polymorphisms in chronic obstructive pulmonary disease. Eur Respir J
2001, 18:748–752.
17. Hegab AE, Sakamoto T, Uchida Y, Nomura A, Ishii Y, Morishima Y, Mochizuki
M, Kimura T, Saitoh W, Kiwamoto T, et al: Association analysis of tissue
inhibitor of metalloproteinase2 gene polymorphisms with COPD in
Egyptians. Respir Med 2005, 99:107–110.
18. Churg A, Wang RD, Tai H, Wang X, Xie C, Dai J, Shapiro SD, Wright JL:
Macrophage metalloelastase mediates acute cigarette smoke-induced
inflammation via tumor necrosis factor-alpha release. Am J Respir Crit
Care Med 2003, 167:1083–1089.
19. Morris DG, Huang X, Kaminski N, Wang Y, Shapiro SD, Dolganov G, Glick A,
Sheppard D: Loss of integrin alpha(v)beta6-mediated TGF-beta activation
causes Mmp12-dependent emphysema. Nature 2003, 422:169–173.
20. Lundblad LK, Thompson-Figueroa J, Leclair T, Sullivan MJ, Poynter ME, Irvin
CG, Bates JH: Tumor necrosis factor-alpha overexpression in lung disease:
a single cause behind a complex phenotype. Am J Respir Crit Care Med
2005, 171:1363–1370.21. Celedon JC, Lange C, Raby BA, Litonjua AA, Palmer LJ, DeMeo DL, Reilly JJ,
Kwiatkowski DJ, Chapman HA, Laird N, et al: The transforming growth
factor-beta1 (TGFB1) gene is associated with chronic obstructive
pulmonary disease (COPD). Hum Mol Genet 2004, 13:1649–1656.
22. Gingo MR, Silveira LJ, Miller YE, Friedlander AL, Cosgrove GP, Chan ED, Maier
LA, Bowler RP: Tumour necrosis factor gene polymorphisms are
associated with COPD. Eur Respir J 2008, 31:1005–1012.
23. Ito M, Hanaoka M, Droma Y, Hatayama O, Sato E, Katsuyama Y, Fujimoto K,
Ota M: The association of transforming growth factor beta 1 gene
polymorphisms with the emphysema phenotype of COPD in Japanese.
Intern Med 2008, 47:1387–1394.
24. Cho MH, Washko GR, Hoffmann TJ, Criner GJ, Hoffman EA, Martinez FJ, Laird
N, Reilly JJ, Silverman EK: Cluster analysis in severe emphysema subjects
using phenotype and genotype data: an exploratory investigation.
Respir Res 2010, 11:30.
25. Castaldi PJ, Cho MH, Cohn M, Langerman F, Moran S, Tarragona N,
Moukhachen H, Venugopal R, Hasimja D, Kao E, et al: The COPD genetic
association compendium: a comprehensive online database of COPD
genetic associations. Hum Mol Genet 2010, 19:526–534.
26. Zhang S, Wang C, Xi B, Li X: Association between the tumour necrosis
factor-alpha-308G/A polymorphism and chronic obstructive pulmonary
disease: an update. Respirology 2011, 16:107–115.
27. Janssens W, Lehouck A, Carremans C, Bouillon R, Mathieu C, Decramer M:
Vitamin D beyond bones in chronic obstructive pulmonary disease: time
to act. Am J Respir Crit Care Med 2009, 179:630–636.
28. Janssens W, Bouillon R, Claes B, Carremans C, Lehouck A, Buysschaert I,
Coolen J, Mathieu C, Decramer M, Lambrechts D: Vitamin D deficiency is
highly prevalent in COPD and correlates with variants in the vitamin
D-binding gene. Thorax 2010, 65:215–220.
29. Wood AM, Bassford C, Webster D, Newby P, Rajesh P, Stockley RA, Thickett
DR: Vitamin D-binding protein contributes to COPD by activation of
alveolar macrophages. Thorax 2011, 66:205–210.
30. Huuskonen O, Kivisaari L, Zitting A, Kaleva S, Vehmas T: Emphysema findings
associated with heavy asbestos-exposure in high resolution computed
tomography of finnish construction workers. J Occup Health 2004, 46:266–271.
31. Piirilä P, Lindqvist M, Huuskonen O, Kaleva S, Koskinen H, Lehtola H, Vehmas
T, Kivisaari L, Sovijärvi AR: Impairment of lung function in asbestos-
exposed workers in relation to high-resolution computed tomography.
Scand J Work Environ Health 2005, 31:44–51.
32. Vierikko T, Järvenpää R, Autti T, Oksa P, Huuskonen M, Kaleva S, Laurikka J,
Kajander S, Paakkola K, Saarelainen S, et al: Chest CT screening of asbestos-
exposed workers: lung lesions and incidental findings. Eur Respir J
2007, 29:78–84.
33. Webb W, Müller N, Naidich D: High-resolution CT of the lung. 2nd edition.
Philadelphia: Lippincott-Raven Publishers; 1996.
34. Viljanen AA: Reference values for spirometric, pulmonary diffusing
capacity and body plethysmographic studies. Scand J Clin Invest Suppl
1982, 159:1–50.
35. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC:
Lung volumes and forced ventilatory flows. Report Working Party
Standardization of Lung Function Tests, European Community for Steel
and Coal. Official Statement of the European Respiratory Society. Eur
Respir J Suppl 1993, 16:5–40.
36. Andreassen CN, Alsner J, Overgaard J, Herskind C, Haviland J, Owen R,
Homewood J, Bliss J, Yarnold J: TGFB1 polymorphisms are associated with
risk of late normal tissue complications in the breast after radiotherapy
for early breast cancer. Radiother Oncol 2005, 75:18–21.
37. Joos L, He JQ, Shepherdson MB, Connett JE, Anthonisen NR, Pare PD,
Sandford AJ: The role of matrix metalloproteinase polymorphisms in the
rate of decline in lung function. Hum Mol Genet 2002, 11:569–576.
38. Ozen S, Alikasifoglu M, Bakkaloglu A, Duzova A, Jarosova K, Nemcova D,
Besbas N, Vencovsky J, Tuncbilek E: Tumour necrosis factor alpha G– > A
−238 and G– > A −308 polymorphisms in juvenile idiopathic arthritis.
Rheumatology 2002, 41:223–227.
39. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of
LD and haplotype maps. Bioinformatics 2005, 21:263–265.
40. Stephens M, Donnelly P: A comparison of bayesian methods for
haplotype reconstruction from population genotype data. Am J Hum
Genet 2003, 73:1162–1169.
41. Lee SY, Kim MJ, Kang HG, Yoo SS, Choi YY, Lee WK, Cha SI, Kim CH, Jung
TH, Park JY: Polymorphisms in matrix metalloproteinase-1, -9 and −12
Kukkonen et al. BMC Pulmonary Medicine 2013, 13:36 Page 10 of 10
http://www.biomedcentral.com/1471-2466/13/36genes and the risk of chronic obstructive pulmonary disease in a Korean
population. Respiration 2010, 80:133–138.
42. Mocchegiani E, Giacconi R, Costarelli L: Metalloproteases/anti-
metalloproteases imbalance in chronic obstructive pulmonary disease:
genetic factors and treatment implications. Curr Opin Pulm Med Suppl
2011, 17:S11–19.
43. Finkelstein R, Ma HD, Ghezzo H, Whittaker K, Fraser RS, Cosio MG: Morphometry
of small airways in smokers and its relationship to emphysema type and
hyperresponsiveness. Am J Respir Crit Care Med 1995, 152:267–276.
44. Satoh K, Kobayashi T, Misao T, Hitani Y, Yamamoto Y, Nishiyama Y, Ohkawa
M: CT assessment of subtypes of pulmonary emphysema in smokers.
Chest 2001, 120:725–729.
45. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A,
Van der Grinten CP, Gustafsson P, Hankinson J, et al: Interpretative
strategies for lung function tests. Eur Respir J 2005, 26:948–968.
46. Lee PH, Shatkay H: F-SNP: computationally predicted functional SNPs for
disease association studies. Nucleic Acids Res 2008, 36:D820–824.
47. Kroeger KM, Carville KS, Abraham LJ: The −308 tumor necrosis factor-
alpha promoter polymorphism effects transcription. Mol Immunol
1997, 34:391–399.
48. Churg A, Wang RD, Tai H, Wang X, Xie C, Wright JL: Tumor necrosis factor-
alpha drives 70% of cigarette smoke-induced emphysema in the mouse.
Am J Respir Crit Care Med 2004, 170:492–498.
49. Rothman KJ: No adjustments are needed for multiple comparisons.
Epidemiology 1990, 1:43–46.
doi:10.1186/1471-2466-13-36
Cite this article as: Kukkonen et al.: Association of genes of protease-
antiprotease balance pathway to lung function and emphysema
subtypes. BMC Pulmonary Medicine 2013 13:36.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
